Cytori Therapeutics, Inc. is a late stage cell therapy company, which engages in the development of autologous cell therapies from adipose tissue, using its proprietary technology, to treat a variety of medical conditions. It offers the Cytori Nanomedicine, Cytori Cell Therapy, and other clinical trials. The company was founded by Ralph E. Holmes and Christopher J. Calhoun in July 1996 and is headquartered in San Diego, CA.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryBiotechnology
SectorMedical
Phone858-458-0900
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$3.67 million
Profitability
Miscellaneous
Employees37
Next Earnings Date5/9/2019 (Estimated)
OptionableOptionable
Cytori Therapeutics (NASDAQ:CYTX) Frequently Asked Questions
What is Cytori Therapeutics' stock symbol?
Cytori Therapeutics trades on the NASDAQ under the ticker symbol "CYTX."
When did Cytori Therapeutics' stock split? How did Cytori Therapeutics' stock split work?
Cytori Therapeutics shares reverse split on Thursday, May 24th 2018. The 1-10 reverse split was announced on Wednesday, May 23rd 2018. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, May 23rd 2018. An investor that had 100 shares of Cytori Therapeutics stock prior to the reverse split would have 10 shares after the split.
How were Cytori Therapeutics' earnings last quarter?
Cytori Therapeutics Inc (NASDAQ:CYTX) issued its earnings results on Monday, April, 1st. The biotechnology company reported ($0.20) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.22) by $0.02. The biotechnology company had revenue of $1.10 million for the quarter. Cytori Therapeutics had a negative net margin of 267.93% and a negative return on equity of 241.90%. View Cytori Therapeutics' Earnings History.
When is Cytori Therapeutics' next earnings date?
What price target have analysts set for CYTX?
2 analysts have issued 1 year price objectives for Cytori Therapeutics' stock. Their forecasts range from $5.00 to $20.00. On average, they anticipate Cytori Therapeutics' share price to reach $12.50 in the next twelve months. This suggests a possible upside of 3,806.3% from the stock's current price. View Analyst Price Targets for Cytori Therapeutics.
What is the consensus analysts' recommendation for Cytori Therapeutics?
2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cytori Therapeutics in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cytori Therapeutics.
What are Wall Street analysts saying about Cytori Therapeutics stock?
Here are some recent quotes from research analysts about Cytori Therapeutics stock:
- 1. Maxim Group analysts commented, "Cytori reported 4Q18 with product sales of $0.4M (celution system) and contract revenues of $0.7M, net loss was ($2.2M). The company ended the period with $5.3M in cash, which does not include the asset sale announced concurrently with earnings." (4/1/2019)
- 2. According to Zacks Investment Research, "Cytori Therapeutics, Inc. is discovering and developing proprietary cell-based therapeutics utilizing adult stem and regenerative cells derived from adipose tissue, also known as fat. The Company's preclinical investigational therapies target cardiovascular disease, spine and orthopedic conditions, gastrointestinal disorders, and new approaches for aesthetic and reconstructive surgery. To facilitate processing and delivery of adipose stem and regenerative cells, Cytori has developed its proprietary Celution System to isolate and concentrate a patient's own stem and regenerative cells in about an hour. This system will dramatically improve the speed in which personalized cell-based therapies can be delivered to patients. " (1/15/2019)
- 3. HC Wainwright analysts commented, "Our valuation for Cytori is based on success with the current therapeutics pipeline with probability of success factors weighted in each therapeutic area. These forecasts feed into our valuation metrics, of free cash flow to the firm (FCFF), discounted EPS (dEPS) and sum- of-the-parts (SOP) models." (9/18/2018)
Has Cytori Therapeutics been receiving favorable news coverage?
Media coverage about CYTX stock has trended positive this week, according to InfoTrie Sentiment. InfoTrie rates the sentiment of press coverage by reviewing more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Cytori Therapeutics earned a daily sentiment score of 2.7 on InfoTrie's scale. They also gave media headlines about the biotechnology company a news buzz of 1.0 out of 10, meaning that recent press coverage is extremely unlikely to have an impact on the company's share price in the near term.
Are investors shorting Cytori Therapeutics?
Cytori Therapeutics saw a drop in short interest in March. As of March 29th, there was short interest totalling 76,608 shares, a drop of 87.4% from the March 15th total of 608,907 shares. Based on an average trading volume of 793,444 shares, the short-interest ratio is presently 0.1 days. Currently, 0.6% of the company's shares are sold short. View Cytori Therapeutics' Current Options Chain.
Who are some of Cytori Therapeutics' key competitors?
Some companies that are related to Cytori Therapeutics include Co-Diagnostics (CODX), Dynatronics (DYNT), Alliqua Biomedical (ALQA), Invivo Therapeutics (NVIV), Biostage (BSTG), Obalon Therapeutics (OBLN), Presbia (LENS), United American Healthcare (UAHC), Neurometrix (NURO), Encision (ECIA), CELLECT BIOTECH/S (APOP), Regenicin (RGIN), Cytocore (MDIT), AdvanSource Biomaterials Corpration (ASNB) and Amedica (AMDA).
What other stocks do shareholders of Cytori Therapeutics own?
Who are Cytori Therapeutics' key executives?
Cytori Therapeutics' management team includes the folowing people:
- Marc H. Hedrick, President, Chief Executive Officer & Director
- Gary S. Titus, Chief Financial Officer
- Mark T. Marino, Chief Medical Officer & Senior Vice President
- John K. Fraser, Chief Scientist
- Russ Havranek, VP-Global Marketing & Business Development
Who are Cytori Therapeutics' major shareholders?
Cytori Therapeutics' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Virtu Financial LLC (0.86%). Company insiders that own Cytori Therapeutics stock include Ag Postfinance and Bank Sa Swissquote. View Institutional Ownership Trends for Cytori Therapeutics.
Which institutional investors are buying Cytori Therapeutics stock?
How do I buy shares of Cytori Therapeutics?
Shares of CYTX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Cytori Therapeutics' stock price today?
One share of CYTX stock can currently be purchased for approximately $0.32.
How big of a company is Cytori Therapeutics?
Cytori Therapeutics has a market capitalization of $5.22 million and generates $3.67 million in revenue each year. The biotechnology company earns $-12,630,000.00 in net income (profit) each year or ($1.71) on an earnings per share basis. Cytori Therapeutics employs 37 workers across the globe.
What is Cytori Therapeutics' official website?
How can I contact Cytori Therapeutics?
Cytori Therapeutics' mailing address is 3020 CALLAN ROAD, SAN DIEGO CA, 92121. The biotechnology company can be reached via phone at 858-458-0900 or via email at [email protected]
MarketBeat Community Rating for Cytori Therapeutics (NASDAQ CYTX)
MarketBeat's community ratings are surveys of what our community members think about Cytori Therapeutics and other stocks. Vote "Outperform" if you believe CYTX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYTX will underperform the S&P 500 over the long term. You may vote once every thirty days.
